Allergan Inc. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Allergan, Inc. (NYSE:AGN) will unveil its latest earnings on Thursday, February 2, 2012. Allergan is a global specialty health care company. It discovers, develops, and commercializes innovative pharmaceuticals, biologics, and medical devices, as well as over-the-counter products.

Allergan, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1 per share, a rise of 13.6% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. Analysts are projecting profit to rise by 15.2% versus last year to $3.64.

Past Earnings Performance: The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked net income of 92 cents per share versus a mean estimate of profit of 90 cents per share.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $1.41 billion in revenue this quarter, a rise of 7.6% from the year ago quarter. Analysts are forecasting total revenue of $5.43 billion for the year, a rise of 11.3% from last year’s revenue of $4.88 billion.

Analyst Ratings: Analysts are bullish on this stock with 15 analysts rating it as a buy, one rating it as a sell and eight rating it as a hold.

A Look Back: In the third quarter, the company swung to a profit of $249.8 million (81 cents a share) from a loss of $670.5 million ($2.21) a year earlier, beating analyst estimates. Revenue rose 9.9% to $1.33 billion from $1.21 billion.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 13.6% in the second quarter from the year earlier, climbed 10.1% in the first quarter from the year-ago quarter and 6.9% in the fourth quarter of the last fiscal year.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH), ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA), Endo Pharmaceuticals (NASDAQ:ENDP), Medicis Pharmaceutical Corp. (NYSE:MRX), Akorn, Inc. (NASDAQ:AKRX), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Merck & Co., Inc. (NYSE:MRK), and Hospira, Inc. (NYSE:HSP).

Stock Price Performance: During November 29, 2011 to January 27, 2012, the stock price had risen $7.44 (9.1%) from $81.38 to $88.82. The stock price saw one of its best stretches over the last year between March 31, 2011 and April 11, 2011 when shares rose for eight-straight days, rising 5.9% (+$4.19) over that span. It saw one of its worst periods between January 12, 2012 and January 19, 2012 when shares fell for five-straight days, falling 1.6% (-$1.40) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?